The Pathologic Classification of Neuroendocrine Tumors: A Review of Nomenclature, Grading, and Staging Systems

Neuroendocrine tumors (NETs) arise in most organs of the body and share many common pathologic features. However, a variety of different organ-specific systems have been developed for nomenclature, grading, and staging of NETs, causing much confusion. This review examines issues in the pathologic assessment of NETs that are common among primaries of different sites. The various systems of nomenclature are compared along with new proposal for grading and staging NETs. Although differences persist, there are many common themes, such as the distinction of well-differentiated (low and intermediate-grade) from poorly differentiated (high-grade) NETs and the significance of proliferative rate in prognostic assessment. A recently published minimum pathology data set is presented to help standardize the information in pathology reports. Although an ultimate goal of standardizing the pathologic classification of all NETs, irrespective of primary site, remains elusive, an understanding of the common themes among the different current systems will permit easier translation of information relevant to prognosis and treatment.

[1]  G. Pelosi,et al.  Typical and Atypical Pulmonary Carcinoid Tumor Overdiagnosed as Small-Cell Carcinoma on Biopsy Specimens: A Major Pitfall in the Management of Lung Cancer Patients , 2005, The American journal of surgical pathology.

[2]  C. Compton,et al.  Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the small intestine and ampulla. , 2010, Archives of pathology & laboratory medicine.

[3]  R. Chetty Requiem for the term 'carcinoid tumour' in the gastrointestinal tract? , 2008, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[4]  C. Compton,et al.  Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the colon and rectum. , 2010, Archives of pathology & laboratory medicine.

[5]  F. Sessa,et al.  Prognostic criteria in nonfunctioning pancreatic endocrine tumours , 1996, Virchows Archiv.

[6]  R. DeLellis Pathology and genetics of tumours of endocrine organs , 2004 .

[7]  Ian M. Jaffee,et al.  Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin. , 2006, Archives of pathology & laboratory medicine.

[8]  S. Willich,et al.  Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. , 2008, Endocrine-related cancer.

[9]  M. Zakowski,et al.  Immunohistochemical staining of cytologic smears with MIB-1 helps distinguish low-grade from high-grade neuroendocrine neoplasms. , 2003, American journal of clinical pathology.

[10]  W. Travis,et al.  Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. , 1998, The American journal of surgical pathology.

[11]  D. Klimstra,et al.  Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Laura H. Tang,et al.  Carcinoid of the Rectum Risk Stratification (CaRRs): A Strategy for Preoperative Outcome Assessment , 2006, Annals of Surgical Oncology.

[13]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[14]  C. Compton,et al.  Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the stomach. , 2010, Archives of pathology & laboratory medicine.

[15]  G. Capurso,et al.  Endocrine tumours of the stomach. , 2005, Best practice & research. Clinical gastroenterology.

[16]  D. Coppola,et al.  Neuroendocrine carcinomas of the lung: a critical analysis. , 2009, American journal of clinical pathology.

[17]  R. Chetty,et al.  Predicting Prognosis in Gastroentero-Pancreatic Neuroendocrine Tumors: An Overview and the Value of Ki-67 Immunostaining , 2008, Endocrine pathology.

[18]  S. Willich,et al.  Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors , 2008, Cancer.

[19]  Laura H. Tang,et al.  Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  G. Apostolou,et al.  The role of cytomorphology and proliferative activity in predicting biologic behavior of pancreatic neuroendocrine tumors , 2009, Cancer.

[21]  A. Scarpa,et al.  TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system , 2007, Virchows Archiv.

[22]  M. Washington,et al.  Pathology Reporting of Neuroendocrine Tumors: Application of the Delphic Consensus Process to the Development of a Minimum Pathology Data Set , 2010, The American journal of surgical pathology.

[23]  R. Jensen,et al.  Gastroenteropancreatic neuroendocrine tumours. , 2008, The Lancet. Oncology.

[24]  R. Steele,et al.  Pulmonary atypical carcinoid: predictors of survival in 106 cases. , 2000, Human pathology.

[25]  R. Arnold Introduction: Definition, historical aspects, classification, staging, prognosis and therapeutic options , 2005 .

[26]  Manal M. Hassan,et al.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Laura H. Tang,et al.  Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms , 2008, Cancer.

[28]  C. Bordi Endocrine tumours of the stomach. , 1995, Pathology, research and practice.

[29]  G. Pelosi,et al.  Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. , 1996, Human pathology.

[30]  B. Weinhold Epigenetics: The Science of Change , 2006, Virchows Archiv.

[31]  R. Arnold Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options. , 2005, Best practice & research. Clinical gastroenterology.

[32]  A. Saqi,et al.  Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids. , 2005, American journal of clinical pathology.

[33]  H. Moch,et al.  Islet 1 (Isl1) Expression is a Reliable Marker for Pancreatic Endocrine Tumors and Their Metastases , 2008, The American journal of surgical pathology.

[34]  F. Bosman,et al.  WHO Classification of Tumours of the Digestive System , 2010 .

[35]  I. Modlin,et al.  Siegfried oberndorfer and the evolution of carcinoid disease. , 2007, Archives of surgery.

[36]  J. Soga Journal of Experimental & Clinical Cancer Research the Term "carcinoid" Is a Misnomer: the Evidence Based on Local Invasion , 2022 .

[37]  C. Compton,et al.  Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the appendix. , 2010, Archives of pathology & laboratory medicine.

[38]  Elisabeth Brambilla,et al.  Pathology and genetics of tumours of the lung , pleura, thymus and heart , 2004 .